Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention

Eric L Simpson, Joanne R Chalmers, Jon M Hanifin, Kim S Thomas, Michael J Cork, W H Irwin McLean, Sara J Brown, Zunqiu Chen, Yiyi Chen, Hywel C Williams, Eric L Simpson, Joanne R Chalmers, Jon M Hanifin, Kim S Thomas, Michael J Cork, W H Irwin McLean, Sara J Brown, Zunqiu Chen, Yiyi Chen, Hywel C Williams

Abstract

Background: Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and is increasing in prevalence. Because of the significant socioeconomic effect of atopic dermatitis and its effect on the quality of life of children and families, there have been decades of research focused on disease prevention, with limited success. Recent advances in cutaneous biology suggest skin barrier defects might be key initiators of atopic dermatitis and possibly allergic sensitization.

Objective: Our objective was to test whether skin barrier enhancement from birth represents a feasible strategy for reducing the incidence of atopic dermatitis in high-risk neonates.

Methods: We performed a randomized controlled trial in the United States and United Kingdom of 124 neonates at high risk for atopic dermatitis. Parents in the intervention arm were instructed to apply full-body emollient therapy at least once per day starting within 3 weeks of birth. Parents in the control arm were asked to use no emollients. The primary feasibility outcome was the percentage of families willing to be randomized. The primary clinical outcome was the cumulative incidence of atopic dermatitis at 6 months, as assessed by a trained investigator.

Results: Forty-two percent of eligible families agreed to be randomized into the trial. All participating families in the intervention arm found the intervention acceptable. A statistically significant protective effect was found with the use of daily emollient on the cumulative incidence of atopic dermatitis with a relative risk reduction of 50% (relative risk, 0.50; 95% CI, 0.28-0.9; P = .017). There were no emollient-related adverse events and no differences in adverse events between groups.

Conclusion: The results of this trial demonstrate that emollient therapy from birth represents a feasible, safe, and effective approach for atopic dermatitis prevention. If confirmed in larger trials, emollient therapy from birth would be a simple and low-cost intervention that could reduce the global burden of allergic diseases.

Keywords: Atopic dermatitis; eczema; emollients; prevention; skin barrier.

Crown Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Figures

Fig 1
Fig 1
Skin barrier protection might prevent atopic dermatitis development. FLG, Filaggrin.
Fig 2
Fig 2
CONSORT flow diagram.

References

    1. Odhiambo J.A., Williams H.C., Clayton T.O., Robertson C.F., Asher M.I. ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124:1251–1258.e23.
    1. Williams H., Stewart A., von Mutius E., Cookson W., Anderson H.R. International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121:947–954.e15.
    1. Yaghmaie P., Koudelka C.W., Simpson E.L. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131:428–433.
    1. Spergel J.M. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105:99–109. 117.
    1. Foisy M., Boyle R.J., Chalmers J.R., Simpson E.L., Williams H.C. Overview of reviews the prevention of eczema in infants and children: an overview of Cochrane and non-Cochrane reviews. Evid Based Child Health. 2011;6:1322–1339.
    1. Boguniewicz M., Leung D.Y. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242:233–246.
    1. Leung D.Y. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;62:151–161.
    1. Brown S.J., McLean W.H. One remarkable molecule: Filaggrin. J Invest Dermatol. 2012;132(3 Pt 2):751–762.
    1. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4:771–788.
    1. Wigger-Alberti W., Elsner P. Petrolatum prevents irritation in a human cumulative exposure model in vivo. Dermatology. 1997;194:247–250.
    1. Ghali F.E. Improved clinical outcomes with moisturization in dermatologic disease. Cutis. 2005;76(suppl):13–18.
    1. Simpson E.L., Berry T.M., Brown P.A., Hanifin J.M. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63:587–593.
    1. Macharia W.M., Anabwani G.M., Owili D.M. Effects of skin contactants on evolution of atopic dermatitis in children: a case control study. Trop Doct. 1991;21:104–106.
    1. Apfelbacher C.J., Diepgen T.L., Schmitt J. Determinants of eczema: population-based cross-sectional study in Germany. Allergy. 2011;66:206–213.
    1. Eichenfield L.F., Tom W.L., Chamlin S.L., Feldman S.R., Hanifin J.M., Simpson E.L. Guidelines of care for the management of atopic dermatitis: Section 1. diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70:338–351.
    1. Simpson E.L., Keck L.E., Chalmers J.R., Williams H.C. How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies. J Allergy Clin Immunol. 2012;130:137–144.
    1. Darmstadt G.L., Mao-Qiang M., Chi E., Saha S.K., Ziboh V.A., Black R.E. Impact of topical oils on the skin barrier: Possible implications for neonatal health in developing countries. Acta Paediatr. 2002;91:546–554.
    1. Darmstadt G.L., Badrawi N., Law P.A., Ahmed S., Bashir M., Iskander I. Topically applied sunflower seed oil prevents invasive bacterial infections in preterm infants in Egypt: a randomized, controlled clinical trial. Pediatr Infect Dis J. 2004;23:719–725.
    1. Edwards W.H., Conner J.M., Soll R.F. Vermont Oxford Network Neonatal Skin Care Study Group. The effect of prophylactic ointment therapy on nosocomial sepsis rates and skin integrity in infants with birth weights of 501 to 1000 g. Pediatrics. 2004;113:1195–1203.
    1. Ghadially R., Halkier-Sorensen L., Elias P.M. Effects of petrolatum on stratum corneum structure and function. J Am Acad Dermatol. 1992;26(3 Pt 2):387–396.
    1. Laquieze S., Czernielewski J., Baltas E. Beneficial use of cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. J Dermatolog Treat. 2007;18:158–162.
    1. Lane A.T., Drost S.S. Effects of repeated application of emollient cream to premature neonates' skin. Pediatrics. 1993;92:415–419.
    1. Danby S.G., AlEnezi T., Sultan A., Lavender T., Chittock J., Brown K. Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care. Pediatr Dermatol. 2013;30:42–50.
    1. Danby S.G., Al-Enezi T., Sultan A., Chittock J., Kennedy K., Cork M.J. The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis. Br J Dermatol. 2011;165:329–334.
    1. Blume-Peytavi U., Cork M., Faergemann J., Szczapa J., Vanaclocha F., Gelmetti C. Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. J Eur Acad Dermatol Venereol. 2009;23:751–759.
    1. Sandilands A., Terron-Kwiatkowski A., Hull P.R., O'Regan G.M., Clayton T.H., Watson R.M. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007;39:650–654.
    1. McAleer M.A., Irvine A.D. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131:280–291.
    1. Hoare C., Li Wan Po A., Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4:1–191.
    1. Szczepanowska J., Reich A., Szepietowski J.C. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol. 2008;19:614–618.
    1. Fallon P.G., Sasaki T., Sandilands A., Campbell L.E., Saunders S.P., Mangan N.E. A homozygous frameshift mutation in the mouse flg gene facilitates enhanced percutaneous allergen priming. Nat Genet. 2009;41:602–608.
    1. Herrick C.A., MacLeod H., Glusac E., Tigelaar R.E., Bottomly K. Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. J Clin Invest. 2000;105:765–775.
    1. Spergel J.M., Mizoguchi E., Brewer J.P., Martin T.R., Bhan A.K., Geha R.S. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest. 1998;101:1614–1622.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe